Kent Hospital
Kent Hospital
Warwick, Rhode Island, United States21 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung adenocarcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-10-08 | NCT04533451 | |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | B-cell chronic lymphocytic leukemia, Chronic Disease, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male Urogenital Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, acute myeloid leukemia, adenocarcinoma, benign urinary system neoplasm, bone marrow disorder, breast disorder, breast neoplasm, carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, esophageal disorder, gastric neoplasm, gastroesophageal junction adenocarcinoma, head and neck carcinoma, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, intestinal disorder, invasive breast carcinoma, kidney cancer, kidney disorder, leukemia, lung disorder, lung neoplasm, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, myeloid leukemia, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, rectal disorder, renal carcinoma, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, sarcoma, skin disorder, skin neoplasm, stomach disorder, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Not stated | 2026-10-02 | NCT05334069 | |
| Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, bronchial neoplasm, bronchogenic carcinoma, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Not stated | 2026-10-02 | NCT03939481 | |
| Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | invasive breast carcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT04379570 | |
| Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT03793179 | |
| Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | Neoplasms by Histologic Type, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, breast carcinoma in situ, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, invasive breast carcinoma, neoplasm, synchronous bilateral breast carcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT01272037 | |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | breast adenocarcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00433511 | |
| Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00310180 | |
| CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | invasive breast carcinoma | Active, not recruiting | Phase 2 | 2026-09-14 | NCT04266249 | |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-09-02 | NCT05879926 | |
| Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-31 | NCT01901094 | |
| Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma | DS Stage I Multiple Myeloma; DS Stage II Multiple Myeloma; DS Stage III Multiple Myeloma | Active, not recruiting | Phase 3 | 2026-07-29 | NCT00644228 | |
| Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-07-01 | NCT03488693 | |
| T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | HER2 positive breast carcinoma, invasive breast carcinoma, synchronous bilateral breast carcinoma | Active, not recruiting | Phase 3 | 2026-06-15 | NCT04457596 | |
| Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | Carcinoma, Ductal, Carcinoma, Lobular, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast disorder, breast ductal adenocarcinoma, breast neoplasm, carcinoma, epithelial neoplasm, invasive ductal breast carcinoma, invasive lobular breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-06-05 | NCT01953588 | |
| Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | HER2-positive Breast Cancer | Active, not recruiting | Phase 3 | 2026-04-27 | NCT05705401 | |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-04-23 | NCT04852887 | |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Early Stage Triple-Negative Breast Carcinoma | Recruiting | Phase 3 | 2025-11-05 | NCT05929768 | |
| EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction | Infarction, Necrosis, Non-ST Elevated Myocardial Infarction, Pathologic Processes, Pathological Conditions, Signs and Symptoms, ST-elevation myocardial infarction, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Phase 4 | 2025-10-06 | NCT05284747 | |
| Rhode Island - Statewide Postpartum Hypertension Remote Surveillance | Female Urogenital Diseases and Pregnancy Complications, Urogenital Diseases, cardiovascular disorder, hypertension, pregnancy-induced, hypertensive disorder, pregnancy disorder, vascular disorder | Recruiting | Not applicable | 2025-06-17 | NCT06842875 | |
| Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colon adenocarcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2025-05-07 | NCT04068103 |